Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;31(12):1202-1211.
doi: 10.1177/0956462420948370. Epub 2020 Sep 14.

Incidence and clearance of penile human papillomavirus infection among circumcised Kenyan men

Affiliations

Incidence and clearance of penile human papillomavirus infection among circumcised Kenyan men

Danielle M Backes et al. Int J STD AIDS. 2020 Oct.

Abstract

Prospective data are limited on human papillomavirus (HPV) acquisition and clearance among circumcised men from resource-limited geographical regions, particularly Africa. The goal of this study was to estimate incidence and clearance of type-specific genital HPV infection in men. Penile exfoliated cell specimens were collected from the glans/coronal sulcus and shaft of 1,037 circumcised Kenyan men at baseline and 6-, 12- and 18-month follow-up visits between 2003-2007. Specimens were tested with GP5+/6+ PCR to detect 44 HPV types. The median age of participants at baseline was 21 years (range 18-28). The 12- and 18-month incidence rates (IRs) for any HPV were 34.9/100 person-years (95% confidence interval [CI]: 31.2-39.0) and 36.4/100 person-years (95% CI: 32.9-40.2), respectively. The 18-month cumulative risk for high-risk HPV was 30% compared to 16% for low-risk HPV. Cumulative risk was not associated with age or anatomical site. The estimated probability of any HPV infection clearing by 12 months was 0.92. Time until HPV clearance was not associated with age, anatomical site, or whether HPV infection type was high-risk or low-risk. HPV IRs among circumcised men in this study were comparable to other circumcised populations.

Keywords: Africa; Human papillomavirus; circumcision; men.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interests: PJFS had received speaker’s fees from Hologic-Gen-Probe, Roche, Abbott, and Qiagen, and has limited stock of Self-Screen, a spin-off company of VU University Medical Center (no payments made); CJLM is an occasional advisory member to QIAGEN, Roche, GSK, Merck and Hologic-Gen-probe, a consultant to QIAGEN (finished 12/31/10), and has small amount of shares of Self-Screen BV (no payments made). JSS has reviewed research grants or served as a consultant for GSK, Merck, Hologic-Gen-probe and QIAGEN. For the remaining authors, none were declared.

Figures

Figure 1:
Figure 1:
Kaplan Meier estimates of the cumulative incidence of human papillomavirus infection. HPV: human papillomavirus; CI confidence interval. A) stratified by high-risk and low-risk HPV status: 18-month incidence proportions= 0.30 (95% CI: 0.28–0.33) for high-risk and 0.16 (95% CI: 0.14–0.18) for low-risk HPV; B) stratified by age group: 18-month incidence proportions =0.30 (95% CI: 0.24–0.36) for ≤19 years, 0.29 (95% CI: 0.25–0.34) for 20–21 years and 0.31 (95% CI: 0.27–0.37 for ≥22 years; and C) stratified by anatomical site: 18-month incidence proportion = 0.33 (95% CI: 0.30–0.36) for glans and 0.30 (95% CI: 0.27–0.33) for shaft.
Figure 2:
Figure 2:
Kaplan Meier estimates for the time to HPV clearance (in months). HPV: human papillomavirus; CI: confidence interval. A) stratified by high-risk and low-risk HPV status: median clearance time for high-risk =6.0 (95% CI: 5.4–11.6) and low-risk =6.0 (95% CI: 5.3–12.2) ; B) stratified by age: median clearance time (months)= 6.02 (95% CI: 5.45–10.96) for ≤19 years, 6.04 (95% CI: 5.54–11.06) for 20–21 years and 6.02 (95% CI: 5.49–11.35) for ≥22 years; and c) stratified by anatomical site: median clearance time for glans=6.0, (95% CI: 5.7–11.2) and shaft = 6.0 (95%CI: 5.6–11.0).

Similar articles

Cited by

References

    1. Bailey RC, Egesah O, Rosenberg S. Male circumcision for HIV prevention: a prospective study of complications in clinical and traditional settings in Bungoma, Kenya. Bull World Health Organ 2008;86(9):669–77. - PMC - PubMed
    1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2(11):e298. - PMC - PubMed
    1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66. - PubMed
    1. New data on male circumcision and HIV prevention: policy and programme implications. Geneva: WHO and UNAIDS; 2007. https://www.who.int/hiv/pub/malecircumcision/research_implications/en/.
    1. Progress in scale-up of male circumcision for HIV prevention in Eastern and Southern Africa: focus on service delivery. Geneva: WHO and UNAIDS; 2011. https://www.who.int/hiv/pub/malecircumcision/mc_country_progress2011/en/.

Publication types